Horizon Pharma (NASDAQ:HZNP) had its price objective upped by Stifel Nicolaus from $25.00 to $35.00 in a research report report published on Thursday morning, The Fly reports. They currently have a buy rating on the biopharmaceutical company’s stock.
Other analysts have also recently issued research reports about the stock. BidaskClub upgraded shares of Horizon Pharma from a buy rating to a strong-buy rating in a research note on Friday, August 10th. Cantor Fitzgerald restated a buy rating and issued a $21.00 target price on shares of Horizon Pharma in a research note on Thursday, September 13th. Morgan Stanley raised their target price on Horizon Pharma from $16.00 to $24.00 and gave the company an equal weight rating in a research note on Friday, August 17th. Jefferies Financial Group raised their target price on Horizon Pharma from $21.00 to $23.00 and gave the company a buy rating in a research note on Thursday, August 9th. Finally, Cowen restated a buy rating and issued a $25.00 target price on shares of Horizon Pharma in a research note on Thursday, August 9th. Five investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Horizon Pharma currently has a consensus rating of Buy and an average target price of $23.00.
Shares of HZNP stock traded down $0.10 on Thursday, reaching $19.30. 1,831,357 shares of the company were exchanged, compared to its average volume of 1,624,805. The stock has a market capitalization of $3.22 billion, a P/E ratio of 18.21, a P/E/G ratio of 1.22 and a beta of 1.29. The company has a quick ratio of 1.63, a current ratio of 1.70 and a debt-to-equity ratio of 2.19. Horizon Pharma has a 1 year low of $12.55 and a 1 year high of $21.25.
In other Horizon Pharma news, EVP Geoffrey M. Curtis sold 9,904 shares of the firm’s stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the transaction, the executive vice president now owns 28,767 shares in the company, valued at $593,463.21. The sale was disclosed in a document filed with the SEC, which is available through this link. 3.90% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Smith Asset Management Group LP bought a new stake in Horizon Pharma in the 3rd quarter valued at $1,931,000. Wells Fargo & Company MN boosted its position in Horizon Pharma by 8.3% during the 3rd quarter. Wells Fargo & Company MN now owns 311,159 shares of the biopharmaceutical company’s stock valued at $6,093,000 after acquiring an additional 23,856 shares in the last quarter. Pitcairn Co. bought a new stake in Horizon Pharma during the 3rd quarter valued at approximately $292,000. Chicago Equity Partners LLC boosted its position in Horizon Pharma by 18.8% during the 3rd quarter. Chicago Equity Partners LLC now owns 212,595 shares of the biopharmaceutical company’s stock valued at $4,163,000 after acquiring an additional 33,656 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its position in Horizon Pharma by 73.8% during the 3rd quarter. State Board of Administration of Florida Retirement System now owns 132,741 shares of the biopharmaceutical company’s stock valued at $2,599,000 after acquiring an additional 56,349 shares in the last quarter. Hedge funds and other institutional investors own 86.87% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Recommended Story: Risk Tolerance
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.